HeartFlow updates investors, emphasizing AI coronary diagnostics

HeartFlow, Inc. ( (HTFL) ) has provided an update.

On January 12, 2026, HeartFlow, Inc. announced it had posted an updated investor presentation on its website ahead of management’s appearance at an investor conference, using the deck to underscore its claim to leadership in AI-driven coronary artery disease diagnostics and to detail its operating and market metrics. The materials highlight strong commercial traction for its HeartFlow Platform, including broad U.S. adoption, a growing installed base for its newer Plaque Analysis product, and last-twelve-month revenue of $162 million with improving non-GAAP gross margins, while also emphasizing the scale of the CAD burden in the U.S. and positioning AI-enabled, CCTA-based imaging as a potential new standard of care versus traditional CAD management. By framing its large addressable market, extensive clinical evidence base, and multiple growth drivers, the company is signaling to investors its confidence in sustained expansion and its competitive positioning in a rapidly evolving cardiovascular imaging and diagnostics landscape, although it also notes significant risks from reimbursement, competitive pressures, technology development, and regulatory requirements.

The most recent analyst rating on (HTFL) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on HeartFlow, Inc. stock, see the HTFL Stock Forecast page.

Spark’s Take on HTFL Stock

According to Spark, TipRanks’ AI Analyst, HTFL is a Neutral.

HeartFlow, Inc. has a low overall stock score due to significant financial instability, including ongoing losses and negative equity. Technical analysis indicates a bearish trend, with some potential for reversal if momentum changes. The absence of valuation metrics further complicates the investment outlook.

To see Spark’s full report on HTFL stock, click here.

More about HeartFlow, Inc.

HeartFlow, Inc. operates in the cardiovascular diagnostics and medical imaging technology industry, positioning itself as a leader in AI technology for the detection and management of coronary artery disease (CAD). The company’s primary products include its HeartFlow FFRCT Analysis and HeartFlow Plaque Analysis, which leverage large datasets of annotated cardiac CT angiography (CCTA) images and extensive intellectual property to improve CAD diagnosis and treatment decisions. HeartFlow targets a sizable and growing U.S. market, citing a current total addressable market of $5 billion, a mid-term U.S. TAM of $6 billion as it moves into asymptomatic populations, an installed base of 1,465 U.S. sites and more than 25,000 active physician customers, underpinned by $162 million in last-twelve-month revenue through the third quarter of 2025 and robust non-GAAP gross margins.

Average Trading Volume: 586,499

Technical Sentiment Signal: Strong Buy

Current Market Cap: $2.85B

Find detailed analytics on HTFL stock on TipRanks’ Stock Analysis page.